Lercanidipine

Lercanidipine is a calcium channel blocker of the dihydropyridine class, specifically designed to treat hypertension. It is marketed under various trade names.

Etymology

The name "Lercanidipine" is derived from the chemical structure of the drug, which is a dihydropyridine calcium antagonist. The prefix "Ler-" is derived from the name of the company that first synthesized the drug, Recordati's Lercanidipine.

Pharmacology

Lercanidipine inhibits the influx of calcium ions through L-type calcium channels in the cell membrane, reducing the amount of calcium available for smooth muscle contraction. This results in vasodilation and a reduction in blood pressure.

Clinical Use

Lercanidipine is used primarily for the treatment of hypertension. It is typically administered once daily, with the dose adjusted according to the patient's response and tolerance. The drug is well tolerated, with the most common side effects being headache, dizziness, and flushing.

Contraindications

Lercanidipine is contraindicated in patients with known hypersensitivity to dihydropyridines, severe hepatic impairment, and in patients with unstable angina or within one month of a myocardial infarction.

Interactions

Lercanidipine may interact with other drugs, including beta blockers, digoxin, warfarin, and cimetidine. It is also known to interact with grapefruit juice, which can increase the concentration of the drug in the bloodstream and enhance its effects.

Related Terms

• Calcium channel blocker
• Dihydropyridine
• Hypertension
• Blood pressure
• Angina
• Myocardial infarction

Lercanidipine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia